ClinicalTrials.Veeva

Menu

Predictors and Clinical Outcomes of Patients With Coronary Heart Disease Co-morbid Depression Post Percutaneous Coronary Intervention (PCICODE)

N

Nanjing Medical University

Status

Active, not recruiting

Conditions

Percutaneous Coronary Intervention
Coronary Heart Disease
Depression

Treatments

Procedure: percutaneous coronary intervention

Study type

Observational

Funder types

Other

Identifiers

NCT03852082
20180317

Details and patient eligibility

About

A prospective, multicenter, registered cohort study to observe the incidence of 1-year major adverse cardiac events in patients with coronary heart disease co-morbid depression treated with percutaneous coronary intervention and to clarify the predictors of 1-year major adverse cardiac events post PCI among these patients.

Full description

Coronary heart disease (CHD) is a clinical relevant psychosomatic issue. Treatment strategies include percutaneous coronary intervention (PCI), guidelines medication (GDMT) and coronary artery bypass grafting (CABG) were clinical proven to be effective to realize myocardial revascularization post CHD. Previous studies revealed that diagnosed depressed CHD patients have 3.6 times higher risk of major adverse events (MACE) post percutaneous coronary intervention than nondepressed. However, a reliable explanation of how depression impact clinical outcomes of CHD patients post PCI is lacking. The objective of this study is to observe the incidence of major adverse cardiovascular events in patients with coronary heart disease co-morbid with depression post PCI, and to explore a prognostic model of clinical outcomes based on physiological, interventional, socio-economic and psychological factors among these patients.

Enrollment

2,600 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Provision of informed consent prior to any study specific procedures;
  2. Men and women 18 years or older;
  3. Diagnosed CHD needed to and can be treated with PCI according to the guidelines of ACC/AHA;
  4. Willingness to participate in the follow-up study for at least 1 year.

Exclusion criteria

  1. Inability to provide written informed consent;
  2. Diagnosed mental illness or medical history (including schizophrenia, bipolar disorder, severe dementia or Lifetime alcohol or substance abuse);
  3. Tendency of suicide;
  4. Pregnant or lactating women;
  5. Any physical or intellectual inability or disability that may affect completion of self-assessment tools, study protocol and follow-up requirements;
  6. Any other reasons that investigators based on professional judgments that would place the patient at increased risk.
  7. Patient with STEMI within 24-hour from the onset of chest pain to admission.

Trial contacts and locations

1

Loading...

Central trial contact

Shaoliang Chen, phd

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems